Keywords
- Postmenopausal Woman
- Mild Cognitive Impairment
- Pelvic Organ Prolapse
- Selective Estrogen Receptor Modulator
- Vaginal Dryness
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, et al. (1999) Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 33:239–247
Agnusdei D (1999) Clinical efficacy of raloxifene in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 85:43–46
Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Carrido L, et al. (2004) Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Am J Obstet Gynecol 191:1979–1988
Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A, et al. (2000) Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 119:1681–1691
Andersson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, Mason T, Anderson PW (2002) Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87:122–128
Bergman A, Karram M, Bahatia N (1990) Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest 29:211–213
Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR (2003) CNS: sex steroids and SERMSs. Ann NY Acad Sci 997:378–88
Bishai R, Arbour L, Lyons C, Koren G (1999) Intrauterine exposure to clomiphene and neonatal persistent hyperplastic primary vitreous. Teratology 60:143–145
Bradbury BD, Lash TL, Kaye JA, Jick SS (2004) Tamoxifen and cataracts: a null association. Breast Cancer Res Treat 87:189–196
Casper RF, McPherson R, Ste-Marie LG (1998) The Canadian Consensus Conference on menopause and osteoporosis. J Soc Obstet Gynaecol Can 20:1243–1272
Cohen FJ, Watts S, Shah A, Akers R, Plouffe L (2000) Uterine effects of three-year raloxifene therapy in postmenopausal women under age 60. Obstet Gynecol 95:104–110
Creamer P, Lim K, George E, Dieppe P (1994) Acute inflammatory polyarthritis in association with tamoxifen. Br J Rheumatol 33:998
Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M (1999) Adverse events reported by postmenopausal women in controlled trialswiths raloxifene. Obstet Gynecol 93:558–565
Duntas LH, Mantzou E, Koutras DA (2001) Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid 11:779–782
Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ (2004) Estrogen-and tamoxifen-associated effects on brain structure and function. Neuro Image 21:364–371
Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261–4271
Gerard B, Bleiberg H (2004) Treatment of hepatocarcinoma. Curr Oncol Rep 6:184–191
Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420–423
Goldstein SR (2002) An update on non-uterine gynaecological effects on raloxifene. Eur J Cancer 38(Suppl 6):S65–S66
Goldstein SR, Nanavati N (2002) Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 187:521–527
Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95–103
Goldstein SR, Neven P, Zhour L, Taylor YL, Ciaccia AV, Plouffe L Jr (2001) Raloxifene effects on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 98:91–96
Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 126:338
Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T (2001) Post-menopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol 97:116–120
Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S, Multiple Outcomes of Raloxifene Evaluation Investigators (2004) Safety and adverse effects associated with raloxifene: multiple outcome of raloxifene evaluation. Obstet Gynecol 104:837–844
Haskell SG, Richardson E (2004) The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn Med 68:355–358
Hendrix LS, McNeeley SG (2001) Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci 949:243–250
Hsu S, Cheng WCh, Jang MW, Tsai KS (2001) Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles. Clin Chem 47:1865–1867
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pil study. Psychooncology 13:61–66
Lacreuse A, Wilson ME, Herndon JG (2002) Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Ag 23:589–600
Martino S, Cauley JA, Barrtt-Connor E, Powles TJ, Mershon J, Disch D, et al. (2004) Continuing outcomes relevant to Evista: Breast cancer incidence in postemenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–1761
Miller CP (2002) SERMSs: evolutionary chemistry, revolutionary biology. Curr Pharm Des 8:2089–2111
Modugno F, Ness RB, Exing S, Cauley JA (2003) Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 101:353–361
Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, et al. (2004) Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15:753–760
Mourits MJ, Bockermann I, de Vries EG, van der Zee AG, ten Hoor KA, van der Graaf WT, Sluiter WJ, Willemse PH (2002) Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86:1546–1550
Muchmore DB (2000) Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5:388–392
Natale V, Albertazzi P, Missiroli N, Pedrini D, Salgarello M (2004) Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study. Maturitas 48:59–63
Neele SJM, Evertz R, Genazzani AR, Luisi M, Netelenbos C (2002) Raloxifene treatment increases plasma levels of β-endorphin in postmenopausal women: a randomized, placebo-controlled study. Fertil Steril 77:1110–1117
Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH (1999) Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24:115–128
Nowak A, Findlay M, Culjak G, Stockler M (2004) Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 3:CD001024
Paganini-Hill A, Clark LJ (2000) Eye problems in breast cáncer patients treated with tamoxifen. Breast Cancer Res Treat 60:167–172
Palomba S, Orio F Jr, Russo T, Falbo A, Amati A, Zullo F (2004) Gonadotropin-releasing hormone agonist with or without raloxifene effects on cognition, mood, and quality of life. Fertil Steril 82:480–482
Reddy A, Prince M, James OF, Jain S, Bassendine MF (2004) Tamoxifen: anovel treatment for primary biliary cirrhosis? Liver Int 24:194–197
Rekers H, Drogendijk AC, Valkenburg HA, Riphagen F (1992) The menopause, urinary incontinence and other symptoms of the genito-urinary tract. Maturitas 15:101–111
Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62:45–51
Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003) Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10:433–439
Shand B, Gilchrist N, Blackwell T, March R (2002) The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial. Clin Hemorheol Microcir 26:249–255
Sherwin BB (2002) Estrogen and cognitive aging in women. Trends Pharmacol Sci 23:527–534
Shilling V, Jenkins V, Fallowfield L, Howell A (2001) The effects of oestrogens and anti-oestrogens on cognition. Breast 10:484–491
Shively CA, Bethea CL (2004) Cognition, mood disorders, and sex hormones. ILAR J 45:189–199
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. and WHIMS Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 289:2651–2662
Stevens HP, Ostlere LS, Black CM, Jacobs HS, Rustin MH (1993) Cyclical psoriatic arthritis responding to anti-oestrogen therapy. Br J Dermatol 129:458–460
Tonelli F, Ficari F, Valanzano R, Brandi ML (2003) Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumore 89:391–396
Tsai CL, Liu TK (1992) Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sci 50:1943–1951
Utian WH, Janata JW, Barbier S, Rosen AS, Mayer MH, Taylor MB (2004) Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) scale. Menopause 11:275–280
Vickers SM, Jhala NC, Ahn EY, McDonald JM, Pan G, Bland KI (2002) Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma). Ann Surg 235:872–878
Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T, Multiple Outcomes of Raloxifene Evaluation Investigators (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207–1213
Zec RF, Trivedi MA (2002) The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 12:65–109
Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintening GM, Supúlveda FV, et al. (1994) Tamoxifen blocks chloride channels: a possible mechanism for cataract formation. J Clin Invest 94:1690–1697
Zhang JJ, Jacob TJ, Hardy SP, Higgins CF, Valverde MA (1995) Lens opacification by antioestrogens: tamoxifen vs ICI 182,780. Br J Pharmacol 115:1347–1348
Zidan J, Rubenstein W (1999) Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology 56:43–45
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Acién, P., Quereda, F., Acién, M.I. (2006). Other Clinical Effects of SERMs. In: Sanchez, A.C., Calaf i Alsina, J., Dueñas-Díez, JL. (eds) Selective Estrogen Receptor Modulators. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-34742-9_13
Download citation
DOI: https://doi.org/10.1007/3-540-34742-9_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-24227-7
Online ISBN: 978-3-540-34742-2
eBook Packages: MedicineMedicine (R0)